Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | $56.00 | Hold → Buy | TD Cowen |
| 3/19/2025 | Outperform → Perform | Oppenheimer | |
| 1/3/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
| 1/19/2024 | $40.00 → $41.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $42.00 | Market Perform | TD Cowen |
TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00
Oppenheimer downgraded Carlyle Group from Outperform to Perform
Wolfe Research upgraded Carlyle Group from Peer Perform to Outperform and set a new price target of $60.00
SoftBank Group Corp. (TSE: 9984, "SoftBank Group") today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere's lead investors – Carlyle (NASDAQ:CG) and Oracle Corp. (NYSE:ORCL) – are selling their respective positions in Ampere. As SoftBank Group broadens its AI infrastructure investments in ventures such as Cristal intelligence and Stargate, the acquisition will help enhance SoftBank Group's capabilities in key areas and accelerate its growt
MCLEAN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, today announced the appointment of Calder Lynch and Jami Snyder to its healthcare advisory board. With decades of experience leading state and federal government healthcare programs, the subject matter experts will advise the company and its clients on healthcare policies and trends as well as strategies to improve health outcomes at a lower cost. "We are excited to welcome Calder Lynch and Jami Snyder to Acentra Health's Healthcare Advisory Boar
MCLEAN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced it has appointed Ezmeralda Sager as Executive Vice President and Chief Transformation Officer (CTO), effective January 6, 2025. In this role, Sager will spearhead enterprise-wide change initiatives to help Acentra Health build upon its strong track record of innovation and execution for its clients. She will provide strategic guidance on process improvements to optimize the development and delivery of the company's products, solutions
Transaction positions company for accelerated growth through improved capital structure and simplified governance LINDON, Utah and NEW YORK, June 4, 2025 /PRNewswire/ -- Trucordia today announced it will receive a $1.3 billion strategic investment from global investment firm Carlyle's Global Credit platform. The transaction will reduce Trucordia's leverage and simplify its governance structure by repurchasing units from existing minority investors. The transaction, which is expected to close this month and values Trucordia at $5.7 billion, provides the company with long-term
New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer
All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right ("CVR") if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December